Point of Care [POC] Diagnostics Market By Product Type (COVID-19 test products, Glucose Monitoring Products, Cardio metabolic Monitoring Products, Infectious Disease Testing Products, Coagulation Monitoring Products, pregnancy & Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drugs-of-abuse Testing Products, Fecal Occult Testing Products, and Other POC Products), By Platform (Lateral Flow Assays, Dipsticks, Micro fluidics, Molecular Diagnostics, and Immunoassays), By Mode of Purchase (Prescription-based Products, and OTC Products),By End User (Clinical Laboratories, Ambulatory Care Facilities and Physician Offices, Pharmacies, retail clinics & E-comm. Platforms, Hospitals Critical Care Centers Urgent care centers, Home Care & Self Testing, and Other End Users)and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East and America – Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data and Forecasts 2022 – 2030

Point of Care [POC] Diagnostics Market Overview

The market is set to pick up speed before very long because of the expansion in subsidizing by various sources, the rising commonness of target sicknesses, and the need to address the new episode of disease.The growing need for home medical care has prompted manufacturers such as Abbott Laboratories and Roche Diagnostics to encourage convenient, easy-to-use products, which is expected to fuel the market.

The decentralisation of medical services, which would be considered common to supply fresh learning opportunities to the general point of care (POC) testing business, is one of the significant patterns seen in continuous consideration.

Market Size

According to Business Intelligence Insights “ Point of Care [POC] Diagnostics Market is expected to grow from USD 45.80 billion in 2021 to USD 67.15 billion by 2030, at a CAGR of 4.90% during the forecast period 2022-2030

Covid -19 Impact Analysis

COVID-19 has generated worldwide interest in demonstrative units that can instantly identify the sickness. Conversely, countries all around the world are suffering from a serious lack of lab-based sub-atomic examinations. As a result, many participants are focusing on increasing the number of examinations available around the world. The increased adoption of point-of-care tests that can quickly analyse COVID-19 will drive significant growth in the point-of-care diagnostics market in 2021. Because of the need for rapid clinical outcomes, purpose behind care testing has become an important indicator device. The constantly rising number of COVID-19 cases, as well as the growing pressure on states to improve patient administration, has fueled demand for quick antibody testing machines that can be used in point-of-care settings.

Market Dynamics

• Drivers

• High prevalence of infectious diseases

• Restraints

• Pricing pressure owing to reimbursement cuts and budget constraints
• Inadequate adoption of point of care diagnostics

Segmentation Insights

In product category the Glucose monitoringdominated the market with more than 28 % of the market share

Glucose monitoring equipment are used to accurately test and track glucose levels in the body, as well as provide data on how much insulin is being delivered. The use of such detecting devices improves glucose control and allows for more accurate treatment options. POC glucose testing kits analyse results with little volumes of blood (usually via a finger prick), making them less detectable when compared to lab tests. More proficient patients can also use these units without difficulty. Patients with type I and type II diabetes can also use glucose checking equipment to monitor their glucose levels and prevent situations.

In Product category the share of Pregnancy & Fertility Testing Productsin the market is more than 38%

Pregnancy & Fertilitytests don't need gifted proficient to perform and can be self-tried by people, in this manner instigating the business extension. For example, First Response pack is a quick pregnancy test that gives bring about 60 seconds. Likewise, Accu-Chek dynamic blood glucose meter unit give brings about 5 seconds to the clients, in this manner moving the interest of market. Furthermore, over the counter test helps in the fast and prior conclusion of irresistible illness, consequently bringing down the danger of local area spread of sicknesses. Likewise, OTC testing additionally lessens the medical services visit of the patients, limiting the dangers of other irresistible sicknesses.

By Product Type:

• COVID-19 test products
• Glucose Monitoring Products
• Cardio metabolic Monitoring Products
• Infectious Disease Testing Products
• Coagulation Monitoring Products
• Pregnancy & Fertility Testing Products
• Tumor/Cancer Marker Testing Products
• Urinalysis Testing Products
• Cholesterol Testing Products
• Hematology Testing Products
• Drugs-of-abuse Testing Products
• Fecal Occult Testing Products
• Other POC Products

By Platform:

• Lateral Flow Assays
• Dipsticks
• Micro fluidics
• Molecular Diagnostics
• Immunoassays

By Mode of Purchase:

• Prescription-based Products
• OTC Products

By End User:

• Clinical Laboratories
• Ambulatory Care Facilities and Physician Offices
• Pharmacies, retail clinics, & E-comm. Platforms
• Hospitals, Critical Care Centers, Urgent care centers
• Home Care & Self Testing
• Other End Users

By Region

• North America

• U.S.
• Canada

• Europe

• Germany
• U.K.
• France
• Italy
• Spain
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• Rest of Asia Pacific

• Latin America

• Brazil

• Mexico
• Rest of Latin America

• Middle East and Africa

• UAE
• South Africa
• Rest of Middle East and Africa (MEA)

Key Players

• Abbott Laboratories (US)
• Siemens Healthineers AG (Germany)
• Quidel Corporation (US)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• Becton, Dickinson and Company (US)
• Chembio Diagnostics (US)
• EKF Diagnostics (UK)
• Trinity Biotech plc (Ireland)
• Instrumentation Laboratory (a Werfen Company) (US)
• Nova Biomedical (US)
• PTS Diagnostics (US)
• Sekisui Diagnostics (US)
• Thermo Fisher Scientific (US)
• bioMérieux S.A. (France)
• DiaSorin S.p.A (Italy)
• AccuBioTech Co., Ltd. (China)
• Meridian Bioscience (US)
• Biocartis Bioscience (Europe)
• GeneSTAT Molecular Diagnostics
• LLC (US)
• Terumo Corporation (Japan)
• Grifols, S.A (Spain)
• ACON Laboratories, Inc. (US)
• A. Menarini Diagnostics s.r.l (Italy)
• OraSure Technologies, Inc. (US)
• Mankind Pharma (India)
• LifeScan IP Holdings, LLC (US)
• Ascensia Diabetes Care Holding AG (Switzerland)
• Fluxergy (US)
• Precision Biosensor Inc. (South Korea)

Regional Insights

World map title will be here...

North Americadominated the market with more than 33% of the market share

North America is the biggest section for point of care diagnostics market concerning area. The United States dominates the North American point-of-care diagnostics market, accounting for the majority of the manufacturing market. This is owing to the country's growing elderly community, as well as other factors such as rising chronic illnesses, proper government regulation, and projects aimed at further developing the medical services framework.

Table

Frequently Asked Questions (FAQ):